picking a clinical trial when youre stage 2 - what actually matters

This is such a smart way to approach it and honestly not everyone thinks to ask these questions before signing on.

Phase matters a lot. Phase 1 is mostly about safety and dosing, phase 2 is where they're starting to look at actual effectiveness. If you're stage 2 and doing reasonably well post-pleurectomy, a phase 2 immunotherapy trial is often where you're seeing the more promising data right now. There was a 2023 study out of Memorial Sloan Kettering looking at nivolumab combinations that showed about 40% disease control rates in pleural cases, which isn't a cure but it's meaningful. Talk to your own doctor about how that applies to your specific pathology.

Looking up the principal investigator is not overkill at all. I started doing that with every family I work with after sitting in on a consult at UCSD in March of last year where the PI had literally published 22 papers on the exact mechanism the trial was studying. That context changed how the family asked questions.

The visit frequency thing is real and I'd never dismiss it as shallow. Showing up consistently matters for your wellbeing and your data quality. A trial you can't sustain isn't serving anyone.

Clinicaltrials.gov lets you see the full protocol, including who's funding it and what the primary endpoints actually are. The endpoint question is the one I'd push hardest on with your oncologist, because "response rate" and "overall survival" are very different goals.

If you're feeling overwhelmed sorting through all this alone, a lot of cancer centers including Scripps have social workers on the oncology team who can sit with you on this stuff. Sometimes just having someone help organize the information makes the decision clearer.

The phase question is the right place to start. Phase 1 trials are primarily about safety, they're finding the right dose, not yet proving the treatment works. Phase 2 is where you start seeing efficacy signals. Phase 3 is comparing against standard of care. For someone who's already had pleurectomy and is stage 2, a Phase 2 immunotherapy combo trial is a very different risk/benefit calculation than a Phase 1 gene therapy trial, and that distinction matters more than the drive to La Jolla.

Looking up the principal investigator is absolutely not overkill. I pulled a PI's publication history once before referring a patient and found they'd published on 47 mesothelioma cases specifically, which told me a lot about their depth of experience in this histology. ClinicalTrials.gov lists the PI for every registered trial and you can search their name in PubMed right after.

The immunotherapy combo question is interesting given where the field is right now. The DREAM3R trial data published in 2023 is reshaping how we think about combination approaches in pleural meso specifically, so asking your oncologist whether the trial you're looking at builds on that or is doing something different is a genuinely good question.

On the weekly vs monthly visit thing, I'd want to know why it's weekly. Is it because the protocol requires frequent tumor assessments, or is it blood draws for safety monitoring? Those are different situations. One means more data on you, the other is just logistics.

Definitely talk to your oncologist at Scripps about getting a second read from a mesothelioma specialist, someone whose entire practice is thoracic malignancies. They can look at your specific pathology from December and tell you whether your tumor profile makes you a better candidate for one mechanism versus the other. That conversation changed treatment direction for patients I've worked with more times than I can count.

What you're doing right now, actually stopping to evaluate instead of just signing up, that's the thing I wish more of my clients did before they called me in a panic three weeks into a trial that wasn't right for them.

So from what I've seen over the years, phase matters a lot. Phase 1 is really about safety and dosing, phase 2 is starting to look at effectiveness. If these are both phase 2 trials you're comparing, that's actually a pretty good position to be in. A 2019 analysis in the Journal of Clinical Oncology found mesothelioma patients in phase 2 immunotherapy trials had meaningfully better response rates when the trial had prior surgical patients enrolled, which given your December pleurectomy is worth asking about specifically.

Looking up the principal investigator is not overkill at all. I had a client here in San Diego who spent about two hours on PubMed just reading the lead researcher's last four publications and it told her more than the consent form did about where that team's head was at.

The weekly versus monthly thing is real and people underestimate how much that grinds on you emotionally over time. Caregiver fatigue, your own exhaustion, it compounds. I've watched people drop out of otherwise solid trials just because the schedule broke them down.

clinicaltrials.gov lets you see the full protocol, endpoints, and sometimes even the stopping rules. That's where I'd spend a Saturday afternoon honestly.

And if anything about this decision starts sitting heavy on you at night, talking to someone who specializes in oncology adjustment isn't weakness, it's just good maintenance.